GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...
GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...
Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Hosted on MSN14d
Is it game over for the GSK share price?If the GSK (LSE: GSK) share price was a video game ... The board has struggled to deliver the promised growth from spinning ...
Bas Vorsteveld will oversee the consumer health company’s Aveeno, Johnson’s Baby, Listerine and Neutrogena brands ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...
Hosted on MSN25d
Is GSK plc (GSK) an Undervalued Defensive Stock for 2025?GSK) is a British global pharmaceutical and healthcare company that develops and markets a wide range of medicines, vaccines, and consumer health products. The company is a leader in immunology ...
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results